Kyle LaHucik
@ky_lahucik
Followers
3K
Following
49K
Media
588
Statuses
5K
reporting on the $, people & startups in biotech land @Endpts | [email protected] | askin Qs, joggin 26.2 | 🗞 📷 🌎 | XC + Track coach | 🏳️🌈
Chicago, IL
Joined July 2014
1st pharma to nab $1 trillion market cap is 149-year-old giant long known for insulin & antidepressant Prozac & based in the “Crossroads of America" But Lilly's obesity drugs drive ~80% of the "economic value" of the company, CEO Dave Ricks recently said https://t.co/VrqtKOVCgL
endpoints.news
Eli Lilly becomes first pharma company to reach $1T valuation, driven by success of GLP-1 drugs Zepbound and Mounjaro under CEO Dave Ricks' leadership.
0
1
6
🚨 banger feature alert🚨 Every detail about one of the most dramatic biotech buyouts in years. From @ArmstrongDrew, @ByLizC and @ky_lahucik. https://t.co/i9VX4QRjf1
endpoints.news
Paul Berns, Clive Meanwell and Whit Bernard Metsera co-founders, navigate bidding war between Pfizer and Novo Nordisk as they fight for $10B deal for the obesity biotech.
0
3
9
Meanwhile, Lilly intensified the amylin race with its Phase 2 data at ObesityWeek, paving the way for Phase 3 enrollment next month https://t.co/oI6o48ENBU
0
0
1
As Pfizer and Novo battle for obesity biotech Metsera, AstraZeneca made a small acquisition of its own in the field on Thursday morning The UK pharma acted on its option to buy activin antibody maker SixPeaks Bio for $170 million at closing https://t.co/pztMvYlWKW
1
0
1
Arena BioWorks shuts down after investors pull plug on big bold bet to reinvent biotech, founder @SchreiberStuart confirmed to me. He pointed to biotech macro conditions and also investors seeking bigger returns on AI and tech. My story for @endpts:
endpoints.news
Arena BioWorks, backed by $500M from billionaires, shuts down after less than 2 years. Founder Stuart Schreiber cites biotech market conditions and investors seeking AI opportunities.
0
3
2
keep thinking about our headline from last month’s story on the Pfizer-Metsera deal background …
0
0
1
BREAKING: LILLY AND NOVO NEAR DEAL WITH THE WHITE HOUSE ON WEIGHT LOSS DRUGS. https://t.co/zHfK6aSfLU
endpoints.news
Eli Lilly and Novo Nordisk are nearing a White House deal to price weight loss drugs at $149 per month in exchange for Medicare coverage, sources say.
2
7
14
Pfizer and Novo Nordisk both increase their bids for Metsera in duel over obesity biotech Metsera agains deems Novo's offer to be "superior." Pfizer is suing Metsera, the startup's board and the Wegovy maker to try to stop the Novo takeover https://t.co/u2iTbYh7HU
endpoints.news
Hours before a pivotal court hearing, Novo Nordisk has increased its offer for obesity biotech Metsera to as much as $10 billion, trying to outdo a new offer by Pfizer.
5
1
5
the Pfizer vs. Metsera and Novo Nordisk situation is getting messy and Metsera thinks Pfizer doesn't have a solid case to support stopping the obesity biotech from going forward with the Wegovy maker https://t.co/jpssmYAYld
endpoints.news
Pfizer and Novo Nordisk's battle over obesity biotech Metsera is getting ugly.
0
0
2
Pfizer sues Metsera & the obesity biotech’s board & Novo Nordisk Wegovy maker made an unsolicited bid for Metsera at higher deal value than Pfizer In its lawsuit, Pfizer said it gave Metsera “such a rich offer” & called Novo’s proposal a “Saturday-night special” @endpts
Breaking news from @ky_lahucik All signs the Novo-Pfizer drama over Metsera is still just getting started https://t.co/ULUmA0gebf
0
0
4
Breaking: Pfizer sues Metsera and Novo Nordisk over Novo's unsolicited proposal to buy the obesity biotech that Pfizer was in the middle of acquiring https://t.co/uRSq5DbDYc
endpoints.news
Pfizer sues Metsera and Novo Nordisk over obesity biotech acquisition.
0
1
1
This team has been resilient all season and shown each other so much love and support. In light of everything that’s going on, it’s been great to see them come together as a family On to Sectionals tomorrow and Detweiller Park for State next weekend! https://t.co/mUUgTl1yFi
blockclubchicago.org
The boys team, made up largely of Mexican Americans, is chasing a rare state championship while their community faces fear and uncertainty.
0
0
1
🚨 NOVO-METSERA-PFIZER SHOW🚨 We're firing up the @endpts emergency stream after Novo tried to steal Metsera from Pfizer. It's me, @ky_lahucik and BMO's Evan Seigerman on what we know, what we're hearing and what's next. $NVO $PFE $MTSR 🎙️230 pm ET🎙️ https://t.co/XgyACtDDzA
endpoints.news
Novo Nordisk makes competing bid for Metsera after Pfizer's earlier offer. Pfizer claims bid violates terms. BMO's Seigerman & LaHucik to discuss on Post-Hoc Live.
0
4
14
And... here's what comes next in the biding war between $NVO and $PFE -- it could get ugly and expensive. From @ky_lahucik
https://t.co/iLn79P045t
endpoints.news
Novo Nordisk and Pfizer in bidding war for Metsera, with Novo offering $1.6B more than Pfizer's $7.3B deal. Both companies ready to raise bids for anti-obesity company.
0
4
4
Novo Nordisk wants Metsera Wegovy maker proposes a $6.5B upfront deal for the obesity biotech a month after Pfizer's $4.9B upfront bid Pfizer wanted Metsera's long-acting injectables + oral treatment candidates to speed drive its weight loss pipeline https://t.co/M0BNQ1z2le
endpoints.news
Novo Nordisk offers $6.5B upfront to acquire Metsera, outbidding Pfizer's $4.9B proposal in battle for obesity drug market position
1
3
6
📣We're hiring! Endpoints News is looking for a deputy editor to join our team in the US, working with amazing reporters like @ky_lahucik, @leilei_wuu + @MaxGelman. It's a chance to join our award-winning newsroom and shape the future of media. https://t.co/IZYxVTbTlL
ats.rippling.com
Deputy Editor, Endpoints News Endpoints is seeking a US-based editor to help run our daily news coverage, working closely with a team of bi...
2
12
17
Some key metrics in biotech showed some strengthening in Q3. And while a single modestly successful IPO doesn't make a trend, an improving $XBI and a focus on deals makes me wonder if the worst is over in biotech. I certainly hope so. https://t.co/6ECITQytFm
endpoints.news
Biotech market shows Q3 recovery with XBI breaking $100, increased M&A activity led by Merck's $10B Verona buyout, and China's rise to 38% of global deals in 2025.
1
3
22
Kristin is a legend. She's an inspiration to everyone on the DWR running team in Chicago. And fellow DWR teammate Brittany Alvarez (whom I've been lucky to train w/for 4 years) was w/in one minute of an OTQ and is a marathoner to watch (top American woman at Honolulu '24)
Here are the American women who ran under the 2:37:00 qualifying standard for the 2028 U.S. Olympic Marathon Trials 🇺🇸 Natosha Rogers – 2:23:28 🇺🇸 Dakotah Popehn – 2:24:21 🇺🇸 Gabriella Rooker – 2:26:32 🇺🇸 Aubrey Frentheway – 2:28:56 🇺🇸 Makenna Myler – 2:29:26 🇺🇸 Maggie Montoya –
0
0
0
now is the best time to build a biotech, says @Jack_O_Meara after steering the early days of RNA liver medicines startup Ochre Bio, O'Meara is back w/a bet on siRNAs + brain shuttles in neurology his London + Dublin biotech, Aerska, now has $21M https://t.co/FhMAdmYOLy
endpoints.news
Aerska launches with $21M seed funding to develop RNAi brain medicines, led by Jack O'Meara. Company aims to create precision treatments for neurodegenerative diseases using brain shuttle tech.
0
2
5
🕵️The case of the dissappering LinkedIn Posts🕳️ Like a lot of folks covering the FDA -- @ZacharyBrennan noted with interest when CDER Director George Tidmarsh made a LinkedIn Post making a big announcement about regulator endpoints + calling out a few cos by name... 🧵
2
4
13